Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Woman charged with illegal DXM sales

This article was originally published in The Tan Sheet

Executive Summary

Yamila Abraham faces prison time and fines for allegedly selling dextromethorphan hydrobromide as a misbranded "herbal alternative" to street drugs. The U.S. district attorney for Nevada alleges said Sept. 21 Abraham sold the misbranded drug as "Snurf," leading to four 10th graders being hospitalized in September 2008. Police suspected the pills contained DXM, an active ingredient in OTC cough suppressants. Sen. Chuck Grassley, R-Iowa, said the hospitalization bolstered the need for legislation to restrict bulk DXM sales. His Dextromethorphan Abuse Reduction Act would set a minimum age for people to purchase DXM products (1"The Tan Sheet" June 29, 2009)

You may also be interested in...



More industry-friendly DXM bill introduced

Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, introduce the Dextromethorphan Abuse Reduction Act June 25 to set an age limit on purchases of the OTC products containing the ingredient. S. 1383, which was referred to the Judiciary Committee, would ban retail sales of DXM OTC products to consumers under 18 years. The legislation differs from a DXM bill then-Sen. Joe Biden introduced in the previous Congress, the Consumer Healthcare Products Association says (1"The Tan Sheet" Sept. 15, 2008). In a change CHPA lobbied for, S. 1383 does not require adding raw DXM to the Controlled Substances Act, the trade group said June 26. Classifying raw DXM as a controlled substance would unnecessarily increase drug firms' regulatory burdens and is not needed to curb abuse of the cough medicine ingredient, according to CHPA

BrightGene Bets On Remdesivir Amid Patent Questions

Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.

QUOTED. 17 February 2020. Ralph Ives.

The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.   

Topics

UsernamePublicRestriction

Register

PS103400

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel